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Background: Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to
70%, does not seem to benefit from the use of anti-EGFR targeted antibodies even in the absence of a mutation of
the K- RAS gene. The EGFR pathway activation via the Ras-Raf-MAP-kinase and the protein-serine/threonine kinase
AKT could determine resistance to anti-EGFR treatment.
Methods: We tested the interaction between phosphorylated AKT and MAPK expression in colorectal tumours and
corresponding metastases and global outcome in K-RAS wild type patients receiving irinotecan-cetuximab.
Results: Seventy-two patients with histologically proven metastatic colorectal cancer, treated with Irinotecan and
Cetuximab based chemotherapy, were eligible for our analysis.
In metastases pAKT correlated with RR (9% vs. 58%, p = 0.004), PFS (2.3 months vs.9.2 months p< 0.0001) and OS
(6.1 months vs.26.7 months p< 0.0001) and pMAPK correlated with RR (10% vs., 47%, p = 0.002), PFS (2.3 months
vs.8.6 months p< 0.0001) and OS (7.8 months vs.26 months p = 0.0004). At multivariate analysis pAKT and pMAPK in
metastases were able to independently predict PFS. pAKT in metastases independently correlated with RR as well
Discussion: pAKT and pMAPK expression in metastases may modulate the activity of EGFR-targeted antibodies. We
could speculate that in patients with pAKT and pMAPK metastases expression targeting these factors may be
crucial.
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Monoclonal antibodies against the ligand-binding site of
the epidermal growth factor receptor (EGFR) have been
shown to improve global outcome of metastatic colorec-
tal cancer patients [1-5]. The introduction of K-RAS
mutational status for patients selection in this setting
appeared to possess the necessary potential for a full
translation into clinical practice of the concept of tar-
geted therapy [5-7].* Correspondence: marioscartozzi@gmail.com
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reproduction in any medium, provided the orIn fact although we are now able to exclude from anti-
EGFR treatment patients with putative refractory colo-
rectal tumours (i.e. those harboring a K-RAS mutant sta-
tus), we are still unable to select responding patients
among those without K-RAS mutations. Clinical obser-
vations suggested that a non negligible proportion of
patients, ranging from 40% to 70%, does not seem to
benefit from the use of anti-EGFR targeted antibodies
even in the absence of a mutation of the K- RAS gene (i.e.
K-RAS wild-type) [2,4-7].
Preclinical observations demonstrated that binding of
specific ligands, such as the epidermal growth factor
(EGF) and transforming growth factor α (TGF-α) to theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the subsequent initiation of the intracellular signalling
pathways cascade. A major downstream signalling route
is via the Ras-Raf-MAP-kinase. Activation of Ras initi-
ates a multistep phosphorylation cascade that leads to
the activation of MAPKs, ERK1, and ERK2, which ulti-
mately regulate transcription of molecules involved in
cell proliferation [8,9]. Another important target in
EGFR signalling is phosphatidylinositol 3-kinase (P13K)
and the downstream protein-serine/threonine kinase
AKT. This latter protein kinase transduces molecular
signals triggering crucial steps for cell growth and
survival [8-10].
It has been also hypothesized that the activation of the
downstream signalling pathway (AKT and MAPK) could
be responsible for EGFR aberrant activity even in the
absence of a detectable EGFR expression [11-14]. In this
case targeting the receptor via monoclonal antibodies
would probably be clinically irrelevant. In fact in non
small cell lung cancer patients it has been suggested that
TKIs responsiveness might be predicted by EGFR down-
stream proteins such as activated (phosphorylated) AKT
[15,16]. However, data regarding the in vivo EGFR-
driven molecular profile in colorectal cancer are conflict-
ing and consequently at the present no speculations are
possible about its role in determining resistance and/or
sensitivity to EGFR-targeted drugs.
In a series of 28 metastatic colorectal patients treated
with gefitinib monotherapy, biologic evaluation of total
and activated EGR, activated AKT, MAP-kinase and Ki
67 on paired pre- and 1 week post- treatment tumour
samples could not confirm a gefitinib-induced decreased
expression of these molecular markers [17].
Moreover no significant correlation has been found
between pAKT expression and clinical outcome in meta-
static colorectal cancer patients treated with cetuximab
[18]. However patients were not stratified for K-RAS
status and therefore firm conclusions were not possible.
A further potential confounding factor in this setting
is the evidence that AKT and MAPK expression in pri-
mary colorectal tumours may not correlate with the ex-
pression in corresponding metastases [19].
We tested the interaction between phosphorylated
AKT and MAPK in primary colorectal tumours and
corresponding metastases and clinical outcome in terms
of response rate (RR), progression free survival (PFS)
and overall survival (OS) in order to identify a group of
K-RAS wild type patients more likely to benefit from
EGFR-targeted treatment.
Methods
Patients selection
Patients with histologically proven metastatic colorectal
cancer, treated with Irinotecan and Cetuximab basedchemotherapy at three different Italian institutions (An-
cona, Fermo, Fabriano) between January 2007 and January
2011 were eligible for our analysis. Tumour response was
evaluated every 8 weeks by clinicians’ assessment and
according to the Response Evaluation Criteria in Solid
Tumours (RECIST).
This study was approved by Ethical committee AOU
Ospedali Riuniti – Umberto I of our institution. All
patients provided informed written consent.
Analysis on the corresponding metastatic site was per-
formed only in case tumour tissue from surgical resec-
tion of metastases was available.K-RAS mutational analysis
Formalin-fixed and paraffin-included tumour samples
were analyzed for KRAS exon 2 mutations, located within
the codon 12 and 13. After the purification using QIA-
quickW PCR Purification kit, the PCR products were direct
sequenced with Big Dye V1.1 Terminator Kit (Applied
Biosystems, Foster City, CA, USA) and an ABI Prism 3100
DNA sequencer (Applied Biosystems).Immunohistochemical analysis
The expression of phospho-AKT (Ser437) and p44/42
MAP kinase, (CELL SIGNALING TECHNOLOGY) was
evaluated with an immunohistochemistry technique on 5-
μm-thick tissue section obtained from paraffin-embedded
specimens fixed in 10% (v/v) neutral buffered formalin.
The sections were deparaffinised and hydrated by
passing through xylene and a graded series of ethanol,
followed by washing in distilled water.
The antigens were unmasked for phospho-AKT
(Ser437) by heat treatment at 98°C 10 min, in EDTA buffer
and for p44/42 MAP kinase by microwave treatment at
98°C 10 minutes, in a 10 mM citrate buffer, pH 6.0. After
antigens retrieval tissues were blocked with 5% normal
goat serum for 60 min.
Subsequently the sections were incubated either with
Phospho-AKT (Ser437) antibody (1:50 dilution) or MAP
kinase antibody (1:100 dilution) overnight at 4°C.
Consecutively immunostaining was performed by the
avidin-biotin peroxidase complex technique (DAKO EN-
VISION SYSTEM) for 30 min. according to the manufac-
turer’s instructions and using 3′, 3′ diaminobenzidine
(DAB, DAKO CYTOMATION) as a chromogen.
Subsequently, the slides were counterstained with
Meyer’s haematoxylin for 1 min., dehydrated in a graded
series of alcohol, treated with xylene and cover slipped.
Positive control of Phospho-AKT (Ser437) and p44/42
MAP kinase staining consisted was performed on paraf-
fin-embedded human breast cancer in all runs. (Data
Sheet of Phospho-AKT (Ser437) and p44/42 MAP kinase
antibodies CELL-SIGNALING TECHNOLOGY).
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AKT (Ser437), p44/42 MAP kinase assay consisted on
sections incubated with secondary alone without pri-
mary antibody in all runs. (Data Sheet of Phospho-AKT
(Ser437) and p44/42 MAP kinase antibodies CELL-SIG-
NALING TECHNOLOGY).
All slides were evaluated independently by two pathol-
ogists (I.B. and A.M.).
Phospho-AKT expression was detected as cytoplasmic
and nuclear staining of neoplastic cells with various in-
tensity. The intensity of Phospho-AKT (Ser473) reactiv-
ity was scored using a four-tier system: 0, no staining, 1
weak, 2 moderate 3 strong.
Positivity for expression Phospho-AKT (Ser473) was
defined as citoplasmatic staining with score 2 and/or 3,Table 1 Patients characteristics and main study results for AK
tumours
Whole Group
(n = 72)
AKT positive
(n = 31)
AKT n
(n = 41
Age (range) 65 (36–80) 67 (41–80) 65 (36
Sex
Males 51 (70%) 20 (65%) 31 (65
Females 21 (30%) 11 (35%) 10 (35
ECOG PS
0–1 58 (81%) 27 (87%) 31 (76
2–3 14 (19%) 4 (13%) 10 (23
Metastatic sites
1 21 (30%) 8 (26%) 13 (32
≥ 2 51 (70%) 23 (74%) 28 (68
Previous lines of treatment
1 10 (14%) 4 (13%) 6 (15%
≥ 2 62 (86%) 27 (87%) 35 (85
Treatment
mFOLFIRI + Cetuximab 28 (39%) 10 (32%) 18 (44
Irinotecan+ Cetuximab 44 (61%) 21 (68%) 23 (56
Response Rate
PR 21 (29%) 5 (16%) 16 (39
SD 19 (26%) 8 (26%) 11 (27
PD 32 (45%) 18 (58%) 14 (34
Survival
m PFS (months) 3.2 2.4 6.5
m OS (months) 17.7 7.8 26.7
ns = not significant
ECOG PS = Eastern cooperative oncology croup performance score
mFOLFIRI = modified FOLFIRI (irinotecan 180 mg/sqm d1, 5FU bolus 400 mg/sqm d
PR = partial remission;
SD = stable disease;
PD = progressive disease;
m PFS = median progression-free survival;
m OS = media overall survival.negativity with score 0 and/or 1. Both the primary and
metastatic neoplasm were considered positive when more
than 1% of the tumour cells had score 2 and/or 3 [20].
p44/42 MAP kinase expression was detected as cyto-
plasmic and nuclear brown staining of neoplastic cells.
The intensity of p44/42 MAP kinase reactivity was
scored using a four-tier system as follows: 0: no staining,
1:weak, 2: moderate, 3:strong signal intensity The pro-
portion of neoplastic cells showing a positive signal was
scored by assessing on a scale of 0 to 1: 0 none; 0,1 less
than one tenth; 0,5 less than one half, and 1,0 greater
than one half. The intensity and proportion scores were
then multiplied to give an H-score; tumours with a
score equal to or higher than 1,0 were deemed positive
[21,22].T and MAPK immunohistochemistry in primary colorectal
egative
)
p value MAPK positive
(n = 32)
MAPK Negative
(n = 40)
p value
–78) ns 65 (38–80) 66 (40–79) ns
%) ns 23 (72%) 28 (70) ns
%) ns 9 (28%) 12 (30%) ns
%) ns 29 (90%) 29 (72%) ns
%) ns 3 (10%) 11 (28%) ns
%) ns 10 (32%) 11 (27%) ns
%) ns 22 (68%) 29 (73%) ns
) ns 3 (9%) 7 (17%) ns
%) ns 29 (91%) 33 (83%) ns
%) ns 12 (37%) 16 (40%) ns
%) ns 20 (63%) 24 (60%) ns
%) ns 9 (28%) 12 (30%) ns
%) ns 7 (22%) 9 (22%) ns
%) ns 16 (50%) 19 (48%) ns
0.0006 3 6 ns
<0.0001 11.2 26.2 ns
1, 5FU 2400 mg/sqm continuous infusion for 46 hrs;
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Statistical analysis was performed with the MedCalc
package (MedCalcW v9.4.2.0).
The association between categorical variables, such as
phosphorylated AKT and phosphorylated MAPK and clin-
ical outcome parameters was estimated by chi-square test.
Survival distribution was estimated by the Kaplan-
Meier method. Significant differences in probability of
relapsing between the strata were evaluated by log-rank
test. A significant level of 0.05 was chosen to assess the
statistical significance.
For statistical analysis overall survival and progression-
free survival were defined respectively as the interval
between the start of cetuximab and irinotecan therapy to
death or last follow-up visit and as the interval between the
start of cetuximab and irinotecan therapy to clinical pro-
gression or death or last follow up visit if not progressed.Table 2 Patients characteristics and main study results for AK
Mets Group
(n= 37)
AKT positive
(n = 23)
AKT ne
(n = 14)
Age (range) 66 (36–80) 67 (36–79) 65 (38–
Sex
Males 27 (73%) 15 (65%) 12 (85%
Females 10 (27%) 8 (35%) 2 (15%)
ECOG PS
0–1 28 (76%) 17 (74%) 11 (78%
2–3 9 (24%) 6 (26%) 3 (22%)
Metastatic sites
1 10 (27%) 6 (26%) 4 (28%)
≥ 2 27 (73%) 17 (74%) 10 (72%
Previous linesof treatment
1 9 (24%) 5 (22%) 4 (28%)
≥ 2 28 (76%) 18 (78%) 10 (72%
Treatment
mFOLFIRI + Cetuximab 12 (32%) 6 (26%) 6 (43%)
Irinotecan+ Cetuximab 25 (68%) 17 (74%) 8 (57%)
Response Rate
PR 10 (27%) 2 (9%) 8 (58%)
SD 9 (25%) 6 (26%) 3 (21%)
PD 18 (48%) 15 (65%) 3 (21%)
Survival
m PFS (months) 3.2 2.3 9.2
m OS (months) 12.6 6.1 26.7
ns = not significant
ECOG PS = Eastern cooperative oncology croup performance score
mFOLFIRI = modified FOLFIRI (irinotecan 180 mg/sqm d1, 5FU bolus 400 mg/sqm d
PR = partial remission;
SD = stable disease;
PD = progressive disease;
m PFS =median progression-free survival;
m OS = median overall survival.Cox multiple regression analysis was used to assess
the role of clinical prognostic factors adjusted for those
variables resulted significant at univariate analysis. Odds
ratios for response were evaluated from multivariate
logistic regression for those variables resulted significant
at univariate analysis.
Tested variables included: age (<65 vs. ≥ 65 years),
gender (female versus male), performance status (East-
ern Cooperative Oncology Group performance score, 0–
1 vs. ≥ 2) and number of metastatic sites (1 vs. ≥ 2),
phosphorylated AKT and MAPK status in primary
tumours and metastases.
Results
Seventy-two patients were included in our study, 51
males (70%) and 21 females (30%). Median age at diag-
nosis was 65 years (range 36–80). Most of the patientsT and MAPK immunohistochemistry in metastases
gative p value MAPK positive
(n = 20)
MAPK Negative
(n = 17)
p value
80) ns 65 (40–80) 66 (40–79) ns
) ns 13 (60%) 14 (82) ns
ns 7 (40%) 3 (18%) ns
) ns 16 (80%) 12 (70%) ns
ns 4 (20%) 5 (30%) ns
ns 5 (25%) 5 (29%) ns
) ns 15 (75%) 12 (71%) ns
ns 5 (25%) 4 (23%) ns
) ns 15 (75%) 13 (77%) ns
ns 7 (35%) 5 (30%) ns
ns 13 (65%) 12 (70%) ns
0.004 2 (10%) 8 (47%) 0.002
ns 5 (25%) 4 (23%) ns
0.001 13 (65%) 5 (30%) 0.006
<0.0001 2.3 8.6 <0.0001
<0.0001 7.8 26 0.0004
1, 5FU 2400 mg/sqm continuous infusion for 46 hrs;
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bination and had more than 1 metastatic sites. Main
clinical characteristics are summarised in Table 1. In 37
cases the corresponding metastatic sites (all liver me-
tastases) were available for AKT and MAPK analysis
(Table 2).
AKT and MAPK results in primary colorectal tumours
AKT was positive in 31 primary colorectal tumours
(43%) and negative in the remaining 41 patients (57%).
MAPK was positive in 32 primary colorectal tumours
(44%) and negative in 40 cases (56%). Clinical character-
istics resulted well balanced across groups (Table 1).Figure 1 Kaplan-Meier curves for median progression free survival (P
cetuximab showing phosphorylated AKT expression (—————) and
primary tumours (A, 2.4 months vs. 6.5 months, p =0.0006) or metastAKT expression in primary tumours correlated with a
statistically significant worse median PFS (2.4 months vs.
6.5 months, p = 0.0006) (Figure 1) and OS (7.8 months
vs. 26.7 months, p< 0.0001) (Figure 2), without any sig-
nificant correlation with RR. No significant correlation
could be found between MAPK expression in primary
tumours and either RR, median PFS or OS (Table 1)
(Figures 3 and 4).AKT and MAPK results in corresponding metastases
Analysis on the corresponding metastatic site was per-
formed in tumour tissue from surgical resection ofFS) of colorectal cancer patients treated with irinotecan and
without phosphorylated AKT expression (———) in either
ases (B, 2.3 months vs. 9.2 months, p =< 0.0001).
Figure 2 Kaplan-Meier curves for median overall survival (OS) of colorectal cancer patients treated with irinotecan and cetuximab
showing phosphorylated AKT expression (—————) and without phosphorylated AKT expression (———) in either primary tumours
(A, 7.8 months vs. 26.7 months, p<0.0001) or metastases (B, 6.1 months vs. 26.7 months, p< 0.0001).
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diagnosis.
AKT was positive in 23 out of the 37 metastases avail-
able for analysis (62%) and negative in the remaining 14
(38%) (Table 2). AKT status in primary colorectal tumours
was not concordant with AKT expression in metastases
in 10 cases (27%). MAPK was positive in 20 metastases
(54%) and negative in 17 cases (46%). MAPK status in
primary colorectal tumours was not concordant with
MAPK expression in metastases in 11 cases (29%).
AKT expression correlated with RR (9% vs., 58%,
p=0.004), median PFS (2.3 months vs.9.2 months p< 0.0001)(Figure 1) and median OS (6.1 months vs. 26.7 months
p< 0.0001) (Figure 2). Analogously MAPK expression in
metastases correlated with RR (10% vs., 47%, p=0.002), me-
dian PFS (2.3 months vs.8.6 months p< 0.0001) (Figure 3)
and median OS (7.8 months vs.26 months p=0.0004)
(Table 2) (Figure 4).Multivariate analysis
Tested variables were: AKT expression in primary
tumours, AKT expression in metastases and MAPK ex-
pression in metastases.
Figure 3 Kaplan-Meier curves for median progression free survival (PFS) of colorectal cancer patients treated with irinotecan and
cetuximab showing phosphorylated MAPK expression (—————) and without phosphorylated MAPK expression (——) in either
primary tumours (A, 3 months vs. 6 months, p = 0.6) or metastases (B, 2.3 months vs. 8.6 months, p =< 0.0001).
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showed that AKT expression in metastases indepen-
dently correlated with response rate (OR= 0.13, 95%CI
0.018–0.9, p = 0.04), whereas neither AKT in primary
tumours nor MAPK in metastases were independently
associated with response.
Multivariate Cox regression analysis indicated that
AKT expression in metastases and MAPK expression in
metastases both correlated with median progression free
survival (HR= 0.63, 95%CI 0.42–0.86, p = 0.0007 and
HR= 0.49, 95%CI 0.28–0.95, p = 0.002 respectively). AKT
expression in primary tumours did not independentlycorrelate with PFS. None of the tested variables indepen-
dently correlated with median overall survival (Table 3).Discussion
The introduction of K-RAS testing for colorectal cancer
patients offered the long-awaited clinical opportunity to
exclude resistant tumours from the treatment with anti-
EGFR antibodies. However a not negligible proportion
of colorectal tumours, ranging from 40 to 70% in differ-
ent series, is still refractory to this therapeutic approach
even in presence of a K-RAS wild type status [2-5].
Figure 4 Kaplan-Meier curves for median overall survival (OS) of colorectal cancer patients treated with irinotecan and cetuximab
showing phosphorylated MAPK expression (—————) and without phosphorylated MAPK expression (———) in either primary
tumours (A, 11.2 months vs. 26.2 months, p = 0.1) or metastases (B, 7.8 months vs. 26 months, p =0.0004).
Table 3 Multivariate analysis results for response rate (RR) and progression-free survival (PFS)
Metastases
AKT Positive AKT Negative MAPK Positive MAPK Negative
Response Rate (%) 9% 58% 10% 47%
Multivariate OR (95%CI) 0.13 (0.018–0.9) 0.26 (0.03–1.95)
Logistic regression p value 0.04 0.9
Median PFS (months) 2.3 9.2 2.3 8.6
Multivariate HR (95%CI) 0.63 (0.42–0.86) 0.49 (028–095)
Cox regression p value 0.0007 0.002
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characterize, either biologically or clinically, this particu-
lar group of patients, who, in the end, receive an inef-
fective therapy at a cost of unwanted side-effects.
Many biological factors have been investigated with
the aim to better identify responding patients in this
setting, however initial observations were often con-
flicting and limited to a small proportion of patients
thus precluding their effective use into the clinical
practice [23-28]. The example of b-RAF is clearly em-
blematic. In fact preliminary data about the role of b-
RAF mutational status seemed initially promising for a
straightforward application in the clinical practice, but
a large subsequent analysis from the CRYSTAL trial
demonstrated that b-RAF although possessing a pos-
sible prognostic role had no predictive value [29,30].
In our analysis we suggested that activated AKT and
MAPK expression in liver metastases could represent
possible molecular determinants for the prediction of
clinical outcome in K-RAS wild type colorectal cancer
patients receiving irinotecan-cetuximab. These observa-
tions are in accordance with the biological assumption
that the activation of the downstream signalling pathway
(pAKT and pMAPK) could be responsible for EGFR
aberrant activity independently from the receptor itself
ultimately making treatment strategies targeting the
EGFR ineffective. A prior study in colorectal cancer
patients could not confirm any correlation between
pAKT expression in primary tumours or metastases and
either response or survival [18]. However in this analysis
the role of phosphorylated AKT was assessed irrespec-
tively of K-RAS status and this may represent a possible
confounding factor for data interpretation. An analysis
presented by Baba et al. showed that pAKT expression
was correlated to good prognosis in colorectal cancer
patients. In this latter study the analysis was conducted
on primary tumours and no information was available
about the treatment administered to the patients. Taken
together these and our observations seem then to sug-
gest that more than a prognostic factor pAKT is a pre-
dictive factor in presence of anti-EGFR inhibitors.
A further relevant finding from our analysis is that
only AKT and MAPK status in metastases is relevant
for the prediction of patients outcome. The variation
(or conservation) of the primary colorectal tumours mo-
lecular profile in distant metastases is a current, but un-
resolved issue in molecular and clinical oncology.
Published analyses in colorectal cancer patients indi-
cated that the mutational status of some molecular
determinants such as K-RAS and BRAF is almost com-
pletely unaltered from primary to corresponding metas-
tases [31]. On the contrary other biological markers
such as EGFR or PTEN, for example, demonstrated a
significant variation [18,32].A discordant pAKT and pMAPK expression in pri-
mary colorectal tumours and metastases has been previ-
ously suggested. A shift in pAKT and pMAPK
expression from primary to metastases has been in fact
reported in as much as 30% of all cases [18,19]. In the
present study a non concordant status between primary
tumours and metastases for AKT and MAPK was
noticed respectively in 27% and 29% of examined cases
thus confirming previous reports. More importantly our
data demonstrated that this different expression pattern
had a biological effect in modulating the activity of
EGFR targeted antibodies, thus reinforcing the hypoth-
esis that when treating metastatic disease with molecu-
larly targeted agents attention should be paid to the
biological markers expression profile in metastases.
Conclusions
We could speculate that in colorectal tumours with pAKT
and pMAPK expression a therapeutic strategy targeting
these molecular factors may be more appropriate than anti-
EGFR therapies. However these assumptions should be
demonstrated before a possible application into the clinic.
We believe that our findings along with others already
reported by other groups may help further composing the
molecular mosaic of K-RAS wild type colorectal cancer
patients especially in view of a prospective validation.
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